Examining GLP-1 peptides as a novel cardioprotective agent for pediatric cardiac surgery

检查 GLP-1 肽作为小儿心脏手术的新型心脏保护剂

• 批准号: 476218
• 负责人: Lao Robert X
• 金额: $ 7.65万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-11-01 至 2025-11-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=476218&lang=en
• 关键词: Heart Failure; Myocardial Protection; Pediatric Hearth Surgery

Heart failure (HF) is a growing medical problem, currently affecting over 1 million Canadians, and is a leading driver of morbidity, mortality and rising health care costs. HF occurs when damaged hearts no longer meet the body's demands. There is no cure

心力衰竭（HF）是一个日益严重的医疗问题，目前影响着超过100万加拿大人，并且是发病率、死亡率和医疗保健成本上升的主要驱动因素。当受损的心脏不再满足身体的需求时，就会发生HF。无法治愈